Durect files response to Posimir CRL; shares up 7% premarket

|About: DURECT Corporation (DRRX)|By:, SA News Editor

DURECT (NASDAQ:DRRX) is up 7% premarket on average volume following its announcement that it has submitted its responses to the CRL it received from the FDA in February 2014 pertaining to its marketing application for pain med POSIMIR (bupivacaine) citing the need for more safety data.

The agency's action date in December 27.

Subscribe for full text news in your inbox